Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.
about
A place for precision medicine in bladder cancer: targeting the FGFRs.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer.Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.Cantharidin alters the expression of genes associated with the NKG2D-associated immune response in TSGH-8301 human bladder carcinoma cells.
P2860
Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Frequency of activating mutati ...... set and regular-onset disease.
@ast
Frequency of activating mutati ...... set and regular-onset disease.
@en
Frequency of activating mutati ...... set and regular-onset disease.
@nl
type
label
Frequency of activating mutati ...... set and regular-onset disease.
@ast
Frequency of activating mutati ...... set and regular-onset disease.
@en
Frequency of activating mutati ...... set and regular-onset disease.
@nl
prefLabel
Frequency of activating mutati ...... set and regular-onset disease.
@ast
Frequency of activating mutati ...... set and regular-onset disease.
@en
Frequency of activating mutati ...... set and regular-onset disease.
@nl
P2093
P2860
P1476
Frequency of activating mutati ...... set and regular-onset disease.
@en
P2093
Anja Rogler
Arndt Hartmann
Christine Spiegelberg
Johannes Giedl
Marc-Oliver Riener
Maximilian Burger
Petra Ruemmele
Robert Stoehr
Thomas Filbeck
P2860
P304
P577
2014-03-15T00:00:00Z